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Porcine brain natriuretic peptide (pBNP) significantly inhibited aldosterone production stimulated by an angiotensin II 
analog and ACTH-stimulated cortisol secretion, together with simultaneously increasing the formation of cGMP in dis- 
persed bovine adrenocortical cells. Receptors for pBNP were identified in bovine adrenal gland using an in vitro receptor 
autoradiographic technique and studies of lz51-pBNP binding. In vitro receptor autoradiography demonstrated specific 
binding sites for ‘2SI-pBNP in bovine adrenal cortex. Complete displacement of 1251-pBNP by unlabeled pBNP or human 
atrial natriuretic peptide (hANP) can take place at these sites. Analysis of ‘ZSI-pBNP binding to bovine adrenocortical 
membrane fractions showed that the adrenal cortex had high-affinity, low-capacity pBNP-binding sites, with a dissocia- 
tion constant (&) of 2.32kO.33 x IO-“’ M (mean *SE) and a maximal binding capacity (B,,,) of 36.7& 1.6 fmol/mg 
protein. Moreover, the specific binding sites for ‘ZSI-pBNP were completely displaced not only by unlabeled pBNP but 
also by unlabeled hANP. The hANP dose required for 50% inhibition of specific lzSI-pBNP binding was almost identical 
to that for pBNP (IC,, values for hANP and pBNP: 8.5 x lO~‘O and 6.5 x lO-‘O M, respectively). These results suggest 
that pBNP exerts a suppressive effect on bovine adrenocortical steroidogenesis via a receptor which may be shared with 
ANP. 
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1. INTRODUCTION 
A newly discovered peptide comprising 26 
amino acid residues, termed porcine brain 
natriuretic peptide (pBNP), has been identified 
and sequenced in porcine brain [ 11. The complete 
amino acid sequence of BNP is remarkably similar 
to, but definitely distinct from that of human atria1 
natriuretic peptide (hANP) [1,2]. pBNP exerts 
natriuretic, diuretic and hypotensive effects on 
anesthetized rats and displays chick rectum relax- 
ant activity to the same extent as rat ANP [l]. The 
natural occurrence of BNP within the mammalian 
brain suggests the possibility that its physiological 
functions may be regulated through a dual 
mechanism involving both ANP and BNP [l]. 
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Recently, Song et al. [3] reported the presence of 
a pBNP-sensitive guanylate cyclase and ‘251- 
pBNP-binding sites in cultured bovine aortic 
smooth muscle cells and endothelial cells. 
However, no studies have been published as yet on 
the mode of action and receptor binding of pBNP 
in adrenal gland. It is well known that ANP in- 
hibits the secretion of aldosterone and other 
steroids, and simultaneously elevates cGMP levels 
in rat, bovine and human adrenal cortex [4-81. 
Here, we have attempted to ascertain the effects of 
pBNP on the secretion of aldosterone and cortisol 
and on formation of cGMP, using dispersed cells 
of bovine adrenal cortex. Moreover, we have tried 
to determine the presence of a specific pBNP- 
binding site in bovine adrenocortical tissue by per- 
forming a ‘2SI-pBNP binding analysis on bovine 
adrenocortical membrane fractions and an in vitro 
receptor autoradiographic technique for bovine 
adrenal tissue. 
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2. MATERIALS AND METHODS 
2.1. Chemicals 
Synthetic pBNP was produced using solid-phase techniques 
and its purity was checked by reverse-phase HPLC [l]. Syn- 
thetic cu-hANP was obtained from the Peptide Institute 
(Osaka). Bovine serum albumin (BSA), phenylmethylsulfonyl 
fluoride (PMSF), leupeptin and chymostatin were purchased 
from Sigma (St. Louis, MO). Dithiothreitol was purchased 
from Katayama (Osaka). Collagenase and Hepes were pur- 
chased from Wako (Osaka). [Asn’,Va15]-angiotensin II was ob- 
tained from Ciba-Geigy (Base]). ACTH (l-18) was obtained 
from Shionogi (Osaka). 
2.2. Materials 
Bovine adrenal glands used in these experiments were col- 
lected from a local abbatoir immediately after slaughter of the 
animals. 
2.3. Cell suspension 
The method of preparing dispersed adrenocortical cells was 
that in [8]. The preparation dispersed cells was resuspended in 
modified Krebs’ solution (135 mM NaCI, 3.5 mM KCI, 2.0 mM 
CaCl2, 1 .O mM MgS04, 20 mM Hepes, pH 7.4; 2 mg/ml 
glucose, 1 mg/ml BSA. The cells were transferred to a 
polypropylene tube (Corning Glass Works, New York). at a 
density of 10’ cells per tube. Preincubations of the dispersed 
bovine adrenocortical cells were carried out for 90 min at 37°C. 
5 min after the addition of various amounts of pBNP, the 
dispersed cells were stimulated with angiotensin II analog (final 
concentration, IO-’ M) or ACTH (final concentration, 
lOma M) for 90 min at 37°C. incubations were terminated by 
centrifugation for 10 min at 1OOOXg. Supernatants were col- 
lected for radioimmunoassay of steroids. To assay cGMP for- 
mation, preincubations were for 10 min at 37°C with 0.5 mM 
I-methyl-3-isobutylxanthine, then cells were incubated with 
various amounts of pBNP for 20 min at 37°C. After centrifuga- 
tion for 10 min at 1000 x g, the supernatants were discarded. A 
I ml aliquot of 6% trichloroacetic acid was added to the cell 
pellets, samples then being sonicated briefly using a Branson 
Sonifier (Danbury, CT). Following centrifugation at 3000 x g 
for 15 min, the supernatants were collected and lyophilized for 
radioimmunoassay. 
2.4. Radioimmunoassay 
Aldosterone and cortisol in the medium were directly 
measured using an RIA kit from Diagnostic Products (Los 
Angeles, CA), cGMP in dispersed cells was assayed with an RIA 
kit from Yamasa Shoyu (Chiba) after syccinylation. The intra- 
assay coefficient of variation was 7% for aldosterone, 8% for 
cortisol and 3.2% for cGMP. 
2.5. ‘z51-pBNP in vitro receptor autoradiography of bovine 
adrenal gland 
In vitro receptor autoradiography was performed as in [8,9]. 
Briefly, adrenal tissues were rapidly isolated and frozen in OCT 
compounds (Division Miles Labs, Naperville, IL) at - 80°C. 
Sections of 25pm thickness were then cut in a cryostat at - 20°C 
and collected on cold microscope slides. Some of the slides were 
used for staining with hematoxylin-eosin. Others were 
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dessicated for at least 3 h under vacuum at - 20°C. For binding 
assays, slide-mounted frozen sections were incubated in 50 mM 
Tris-HCI buffer (pH 7.4), containing 100 mM NaCI, 5 mM 
MgC12, 0.5rg/ml PMSF, 40ag/ml bacitracin, 4pg/ml leupep- 
tin, 2 fig/ml chymostatin and 0.5% bovine serum albumin at 
room temperature for 1 h with 50 pM ‘*‘I-pBNP for total bin- 
ding, and 50 pM “‘1-pBNP plus 100 nM unlabeled pBNP for 
nonspecific binding. Another slide section was incubated with 
50 pM ‘*‘I-pBNP plus 100 nM unlabeled cu-hANP. At the end 
of the incubation period, slides were rinsed three times in cold 
50 mM Tris-HC1 buffer and rapidly dried. These slides were 
tightly juxtaposed with Kodak XAR film and stored at - 80°C 
for 6 days. After exposure films were processed. Specific bin- 
ding was evluated from the difference in ‘251-pBNP bound in the 
absence and presence of 100 nM unlabeled pBNP. 
2.6. Binding of “‘I-pBNP to bovine adrenocortical membrane 
fractions 
Bovine adrenocortical tissue was minced finely and 
homogenized with a Polytron (Kinematica Kriens, Switzerland) 
in 10 vols ice-cold 50 mM Tris-HCI buffer (pH 7.6). containing 
1 mM EDTA, 1 mM dithiothreitol and 0.1 mM PMSF. The 
homogenate was centrifuged at 800 x g for 10 min, the resultant 
pellet being suspended in 3 vols of the same buffer and cen- 
trifuged under identical conditions. The supernatant fractions 
were combined and centrifuged at 3OOOOxg for 30 min. The 
resultant pellet was stored at - 80°C. All operations were con- 
ducted at 4°C. pBNP was iodinated using the lactoperoxidase 
method and purified by reverse-phase HPLC. The specific ac- 
tivity of ‘2SI-pBNP amounted to 4 mCi/nmol. 
Binding of ‘*‘I-pBNP to bovine adrenocortical membrane 
fractions was determined as in [lo]. The standard binding assay 
was conducted at a final pH of 7.6 in 250 ~1 of 50 mM Tris- 
HCI, containing 1 mM EDTA, 1 mM cystamine, 150 mM 
NaCl, 5 mM MnC12, 0.1 mM PMSF, 50-200 pg adrenocortical 
membrane fractions and 5-300 pM ‘*‘I-pBNP, with or without 
100 nM BNP. Incubation was carried out at 22°C for 45 min 
in a polystyrene culture test tube (12 x 75 mm) (Elkey Products, 
Shrewsbury, MA). Bound ‘2SI-pBNP was separated from free 
ligand by filtration on a 934 AH glass-fiber filter (Whatman, 
Clifton, NJ) which had been pretreated with 0.3% (w/v) 
polyethylenimine. The filters were washed 3 times with 3 ml 
phosphate-buffered saline and counted using a gamma-counter 
(Aloka auto well gamma-system ARC-60, Tokyo, Japan). 
Specific binding was calculated by subtraction from the total 
binding of binding obtained in the presence of 100 nM un- 
labeled pBNP. The protein concentration of the suspension was 
determined according to Lowry et al. [ll] using BSA as 
standard. 
3. RESULTS 
3.1. Effect of pBNP on formation of cGMP and 
secretion of steroids 
As shown in fig.1, pBNP stimulated cGMP for- 
mation in bovine adrenocortical cells in a dose- 
dependent manner. The basal level of cGMP for- 
mation was 24 fmol/lO’ cells per 20 min. With 
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of aldosterone and cortisol stimulated by 10e7 M 
angiotensin II analog or lo-’ M ACTH. With 
1O-7 M angiotensin II analog, aldosterone secre- 
tion of the dispersed bovine adrenocortical cells 
was 0.77 ng/lO’ cells per 90 min. Apparently, 
pBNP inhibited aldosterone secretion dose- 
dependently. Maximum inhibition was obtained at 
1O-8 M pBNP, with which aldosterone secretion 
decreased to 0.3 ng/105 cells per 90 min. The 1% 
of pBNP in the suppression of aldosterone secre- 
tion was approx. 3x lo-” M (fig.2A). With 
lo-* M ACTH, secretion of aldosterone and cor- 
tisol amounted to 0.75 and 5.9 ng/105 cells per 90 
min, respectively. pBNP significantly inhibited 
secretion of both aldosterone and cortisol in a 
dose-dependent manner. Maximum inhibition of 
secretion of aldosterone and cortisol was observed 
with lo-’ M pBNP, which resulted in the level of 
Fig.1. Effect of pBNP on formation of cGMP in bovine 
adrenocortical cells. Each point represents the mean rf- SE 
(n=3). 
lo-’ M pBNP, intracellular cGMP formation in- 
creased 5-fold over the unstimulated level 
(128 fmol/lO’ cells per 20 min). The EC50 of 
pBNP in cGMP formation was approx. 
3 x lo-” M in dispersed bovine adrenocortical 
cells. 
aldosterone secretion being reduced to 0.22 ng/lO’ 
cells per 90 min and in cortisol secretion falling to 
40% of that in the absence of pBNP. The ICso of 
pBNP for the suppression of aldosterone secretion 
was approx. 3 x lo-” M (fig.2B,C). 
3.2. In vitro receptor autoradiography of 12jI- 
pBNP in bovine adrenal gland 
Fig.3 shows the localization by autoradiography 
of “‘1-pBNP-binding sites in cross-sections of 
Fig.2 shows the effect of pBNP on the secretion 
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Fig.2. Effect of pBNP on aldosterone (A,B) and cortisol (C) production stimulation by angiotensin II or ACTH in bovine 
adrenocortical cells. Each point represents mean + SE (n = 3). 
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Fig.3. Autoradiography of “‘1-BNP binding to bovine adrenal gland. On the left a schematic illustration of a section of bovine adrenal 
gland is shown. 
recognized throughout the entire adrenal cortex. In 
particular marked uptake of 1251-pBNP was noted 
in the zona glomerulosa of adrenal cortex. Excess 
amounts of unlabeled pBNP significantly inhibited 
‘251-pBNP binding of the adrenocortical region. In 
addition, the 1251-pBNP-binding site was also 
displaceable by unlabeled hANP. On the other 
hand, we found no difference in ‘2sI-pBNP 
binding in the presence or absence of 100 nM un- 
labeled pBNP in adrenal medulla. 
3.3. Binding of ‘251-pBNP to adrenocortical 
membrane fractions 
Fig.4 shows saturation data for 1251-pBNP 
binding to adrenocortical membrane fractions. 50 
pg cell membranes was incubated with ‘251-pBNP 
ranging from 5 to 300 pM in the presence or 
absence of 100 nM unlabeled pBNP at 22°C for a 
period of 45 min. Specific binding reached a 
plateau around 150 pM 12’I-pBNP. Scatchard 
plots of ‘*?-pBNP specific binding gave a straight 
line, from which the & and B,,, were estimated to 
be 2.32kO.33 x 10-i’ M and 36.7 + 1.6 fmol/mg 
protein, respectively. Fig.5 shows the displacement 
curve for “‘1-pBNP in adrenocortical membrane 
fractions by the various concentrations of unla- 
beled hANP and pBNP. Unlabeled pBNP in- 
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hibited “‘1-pBNP binding to adrenocortical 
membrane fractions in a dose-dependent manner. 
The actual dose of unlabeled pBNP required for 
50% inhibition was estimated to be 6.5 x lo-” M. 
Unlabeled hANP also showed equipotent in- 
hibitory effect on 12’I-pBNP specific binding to 
unlabeled pBNP. 
4. DISCUSSION 
It has been reported that synthetic a-hANP 
significantly inhibits secretion of aldosterone, cor- 
tisol and DHEA in cultured bovine adrenocortical 
cells [8]. Moreover, specific binding sites for 1251- 
hANP were visualized in the glomerulosa and 
fasciculata-reticularis zones of bovine adrenal 
gland by in vitro ‘251-hANP receptor auto- 
radiography [S]. 
The present study clearly shows that pBNP ex- 
erts a suppressive effect on angiotensin II analog- 
stimulated secretion of aldosterone, and on secre- 
tion of aldosterone and cortisol stimulated by 
ACTH in bovine adrenocortical cells. Although it 
is questionable whether cGMP functions as a 
second messenger in the action of ANP in 
adrenocortical cells, Matsuoka et al. [6] 
demonstrated that the suppresive effect of ANP 
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Fig.4. Saturable binding of “‘1-pBNP to adrenocortical membrane fractions. Specific binding in the presence of 100 nM unlabeled 
pBNP. Each point is the mean of two experiments. (Inset) Scatchard plot of the binding data. Ratio of bound to free ‘*‘I-pBNP is 
plotted vs concentration of bound ‘ZS1-pBNP. 
was inversely related to the increase in cGMP for- 
mation in the dispersed bovine adrenocortical 
cells, suggesting that the formation of cGMP may 
provide a good metabolic indication of the action 
of the ANP in aldosteronogenesis. The present 
study also shows that the EC50 value of pBNP for 
the increase in cGMP formation was almost iden- 
tical to the I& values for the suppression of secre- 
tion of aldosterone and cortisol, suggesting that 
the increase on cGMP formation reflects the 
metabolic effect of pBNP in bovine adrenocortical 
cells. 
Since pBNP is as potent as cr-hANP in inhibiting 
secretion of aldosterone and cortisol in bovine 
adrenocortical cells, pBNP may act on a bovine 
adrenocortical cells in the same manner as that in 
a-hANP. The number of amino acid residues of 
pBNP is different from that of cu-hANP, however, 
the highest homology was observed between pBNP 
and a-hANP (4-28) [l]. This structural 
resemblance led us to investigate the possibility of 
whether 1251-pBNP could bind functional hANP 
receptor. 
We have demonstrated that the bovine adrenal 
cortex possesses pBNP-binding sites by using an in 
vitro receptor autoradiographic technique and per- 
forming binding studies on “‘1-pBNP. Scatchard 
plots of the binding data gave a straight line, in- 
dicating a single population of pBNP receptors 
with a & of 2.32x lo-” M and B,,, of 36.7 
fmol/mg protein. The pattern of distribution of 
1251-pBNP-binding sites visualized by autoradiog- 
raphy was very similar to that in ‘251-hANP of 
bovine adrenal gland and the ‘251-pBNP specific 
binding site was displaceable by unlabeled hANP 
as well as pBNP [8], suggesting that the bovine 
adrenal cortex may possess a common receptor for 
both hANP and pBNP. In hANP, the 17-amino- 
acid ring structure enclosed by a cysteine-cysteine 
disulfide bridge may be important for the receptor 
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Fig.5. Competitive binding of “‘1-pBNP to adrenocortical membrane fractions by unlabeled hANP and pBNP. 
binding and biological activity of hANP [12-151. 
The present data suggest that the most important 
region in the binding of hANP to the receptor may 
be 13 amino acid residues except at least 4 amino 
acid sequences (a-hANP 7,9,14,15). It has been 
reported that the specific ANP receptor sites are 
localized in some area of mammalian brain, and 
may be important sites for the central regulation of 
water and electrolyte metabolism [ 161. The specific 
binding sites for hANP in brain tissues may func- 
tion as a pBNP receptor and subsequently 
modulate cardiovascular and fluid balance 
regulation. 
In conclusion, pBNP has an inhibitory effect on 
bovine adrenocortical steroidogenesis. The high- 
affinity-low-capacity pBNP receptor, which may 
be identical to the ANP receptor, could mediate 
such a specific, hormonal action of pBNP in 
bovine adrenal cortex. 
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